Survey on Current Status and Treatment of Hepatitis and Liver Cancer in the Asia-Pacific Region

Survey on Current Status and Treatment of Hepatitis and Liver Cancer in the Asia-Pacific Region - A-HOC(APASL Hepatology/Oncology Consortium)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000050649

Enrollment

10000

Registered

2023-03-23

Start date

2023-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients diagnosed with HCC at the collaborating institution beginning January 1, 2013, including newly diagnosed patients during the study enrollment period.

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients diagnosed with HCC at the collaborating institution beginning January 1, 2013, including newly diagnosed patients during the study enrollment period.

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Overall survival from the time of diagnosis of HCC.	—

Secondary

Measure	Time frame
Diagnostic methods used as the basis for the diagnosis of HCC Evaluation of liver function at the time of detection and the degree of progression of HCC Causes of background liver damage Sequence and combination of treatments Status and efficacy of new drugs	—

Countries

Japan,Asia(except Japan)

Contacts

Public ContactIzumi Nakano

Asian Pacific Association for the Study of the Liver (APASL) Secretariat

apasl_secretariat@apasl.info03-5312-7686

Outcome results